bpc 157 and tirzepatide 10mg — Dual Receptor Agonist (GLP-1/GIP) — Research Peptid – Prime Labs The Peptide Labs | High-Purity

Diarrhea was reported across all dose groups but was significantly more frequent and more severe at higher doses

Fainting or loss of consciousness

After four weeks, evaluate whether symptoms have improved

Because the compounds are formulated together in precise proportions, patients avoid the unpredictability of timing two separate medications

MAD doses ranged from 0.2 to 0.6 mg once weekly for 6 weeks (ClinicalTrials.gov Identifier: NCT04389775)

Retatrutide (LY3437943), developed by Eli Lilly, is an investigational once-weekly injectable triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously